Emma Reeve - 02 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Reporting relationship: Director
Issuer ticker: PTCT
Reported as of: 02 Jan 2026
Net transaction value: -$21,624
SEC form: 4
Accepted by SEC: 06 Jan 2026, 17:20:23 UTC
Prior SEC filing: 05 Dec 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Avraham S. Adler, Attorney-in-Fact

Key filing fact

Emma Reeve filed Form 4 for PTC THERAPEUTICS, INC. (PTCT) on 06 Jan 2026.

Key facts

This page summarizes Emma Reeve's Form 4 filing for PTC THERAPEUTICS, INC. (PTCT).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 17:20.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: -$21,624.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001680329 Primary reporting owner

Reeve Emma

Relationship: Director
Address: C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN
Signature: /s/ Avraham S. Adler, Attorney-in-Fact
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTCT transaction

Common Stock

Award

Transaction value: $0
Shares: +4,000
Change %: +60%
Price: $0.000000
Shares after: 10,666
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

PTCT transaction

Common Stock

Options Exercise

Transaction value: $34,160
Shares: +734
Change %: +6.9%
Price: $46.54
Shares after: 11,400
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F2

PTCT transaction

Common Stock

Sale

Transaction value: $55,784
Shares: -734
Change %: -6.4%
Price: $76.00
Shares after: 10,666
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTCT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +3,475
Change %
Price: $0.000000
Shares after: 3,475
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,475
Exercise price: $76.74
Footnotes: F3

PTCT transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -734
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 05 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 734
Exercise price: $46.54
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.

Footnote F2

This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.

Footnote F3

This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.

Footnote F4

Currently exercisable.